Maternal/Pediatric Respiratory Syncytial Virus (RSV) Work Group

Sarah S. Long, MD
Chair, Maternal/Pediatric RSV Work Group

ACIP General Meeting
August 3, 2023
# Work group members (External)

<table>
<thead>
<tr>
<th><strong>ACIP Members</strong></th>
<th><strong>Ex Officio Members</strong></th>
<th><strong>Consultants</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarah Long (chair)</td>
<td>Rachel Zhang (FDA-CBER)</td>
<td>Cody Meissner (Dartmouth Geisel School of Medicine)</td>
</tr>
<tr>
<td>Pablo Sanchez</td>
<td>Nicholas Geagan (FDA-CBER)</td>
<td>Helen Chu (University of Washington)</td>
</tr>
<tr>
<td>Oliver Brooks</td>
<td>Judy Beeler (FDA-CBER)</td>
<td>Natasha Halasa (Vanderbilt University)</td>
</tr>
<tr>
<td>Camille Kotton</td>
<td>Yodit Belew (FDA-CDER)</td>
<td>Denise Jamieson (Emory University School of Medicine)</td>
</tr>
<tr>
<td></td>
<td>Prabha Viswanathan (FDA-CDER)</td>
<td>Daniel Feikin (World Health Organization)</td>
</tr>
<tr>
<td></td>
<td>Sonnie Kim (NIH-NIAID)</td>
<td>Carol Baker (University of Texas Health Science Center)</td>
</tr>
<tr>
<td></td>
<td>April Killikelly (Public Health Agency of Canada)</td>
<td>Kevin Ault (Western Michigan University)</td>
</tr>
<tr>
<td></td>
<td>Winnie Siu (Public Health Agency of Canada)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Valerie Marshall (OIDP/OASH)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jessica Lee (CMS/CMCS)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Terry Dalle-Tezze (HRSA)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lucia Lee (FDA-CBER)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Robin Wisch (FDA-CBER)</td>
<td></td>
</tr>
</tbody>
</table>

**Liasons**

James McAuley (IDSA)
Patsy Stinchfield (NFID)
Brenna L. Hughes (ACOG)
Nicole Chaisson (AAFP)
Sean O’Leary (AAP)
Jennifer Schuster (PIDS)
Molly Howell (AIM)

**GRADE/EtR Consultants**

Doug Campos-Outcalt
Rebecca Morgan
Work group members (CDC)

**CDC**
- Katherine Fleming-Dutra (co-lead)
- Jefferson Jones (co-lead)
- Meredith McMorrow
- Mila Prill
- Natalie Thornburg
- Aron Hall
- Ismael Ortega-Sanchez
- Melissa Coughlin
- Jamison Pike
- Lauren Roper

- Amber Winn
- Chris Taylor
- Tami Skoff
- Angie Campbell
- Michael Melgar
- Amanda Payne
- Nicole Dowling
- Noelle Molinari
- Claire Midgley
- Fiona Havers
- Pragna Patel
- Andrea Sharma
- Amadea Britton
- Ruth Link-Gelles
- Danielle Moula
- Megan Wallace
- Monica Godfrey
- Karen Broder
- Naomi Tepper
- Heidi Moline
- Hannah Rosenblum
- Derrell Powers
- Raigan Wheeler
- Sally Ezra
- Elizabeth Greene
- Manisha Patel
- Tom Shimabukuro
- Demorah Hayes
- Latifah Boyce
- A. Patricia Wodi
- Neil Murthy
- Christine Olson
- Anne Hause
- Andrew Leidner
- David Shay
- Sarah Meyer

**CDC ACIP Staff**
- Melinda Wharton
- Stephanie Thomas
- Jessica MacNeil
Previous maternal/pediatric RSV ACIP presentations on nirsevimab

- Epidemiology and burden of RSV in infants
- Virology and immunology of RSV
- Safety and efficacy of nirsevimab
- Cost effectiveness analysis for nirsevimab – CDC model
- Cost effectiveness analysis for nirsevimab – Comparison with manufacturer model
- Evidence to Recommendations framework for nirsevimab
- Clinical considerations for nirsevimab
Agenda: Thursday August 3, 2023

- Evidence to Recommendations Framework for nirsevimab  
  Dr. Jefferson Jones (CDC)
- Nirsevimab implementation considerations  
  Dr. Georgina Peacock (CDC)
- Clinical considerations for nirsevimab  
  Dr. Jefferson Jones (CDC)
- Workgroup considerations and proposed recommendations and voting language  
  Dr. Jefferson Jones (CDC)
- Vaccines for Children Resolution  
  Dr. Jeanne Santoli (CDC)
For more information, contact CDC
1-800-CDC-INFO (232-4636)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Proposed ACIP Voting Language

- Infants aged <8 months born during or entering their first RSV season are recommended to receive one dose of nirsevimab (50 mg for infants <5 kg and 100 mg for infants ≥5 kg)

- Children aged 8–19 months who are at increased risk of severe RSV disease and entering their second RSV season are recommended to receive one dose of nirsevimab (200 mg)